Enfusion, Inc. (NYSE:ENFN – Get Free Report) CTO Dan Groman sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $9.97, for a total transaction of $49,850.00. Following the completion of the sale, the chief technology officer now owns 133,828 shares in the company, valued at $1,334,265.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Dan Groman also recently made the following trade(s):
- On Tuesday, October 17th, Dan Groman sold 5,000 shares of Enfusion stock. The shares were sold at an average price of $9.09, for a total transaction of $45,450.00.
- On Tuesday, September 19th, Dan Groman sold 5,000 shares of Enfusion stock. The shares were sold at an average price of $9.07, for a total value of $45,350.00.
Enfusion Price Performance
ENFN opened at $10.11 on Friday. The business has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.09. Enfusion, Inc. has a 12 month low of $7.37 and a 12 month high of $13.06. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 126.39, a PEG ratio of 2.38 and a beta of 0.81.
Analysts Set New Price Targets
Hedge Funds Weigh In On Enfusion
Several hedge funds and other institutional investors have recently made changes to their positions in ENFN. Envestnet Asset Management Inc. acquired a new position in Enfusion during the 1st quarter worth approximately $128,000. Bank of New York Mellon Corp lifted its position in shares of Enfusion by 1,435.5% during the 1st quarter. Bank of New York Mellon Corp now owns 762,883 shares of the company’s stock worth $9,704,000 after purchasing an additional 713,201 shares during the last quarter. Citigroup Inc. grew its stake in shares of Enfusion by 24.2% during the first quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock worth $91,000 after purchasing an additional 1,390 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Enfusion by 55.4% in the first quarter. MetLife Investment Management LLC now owns 14,206 shares of the company’s stock valued at $181,000 after buying an additional 5,065 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Enfusion by 33.6% during the 1st quarter. Rhumbline Advisers now owns 21,723 shares of the company’s stock worth $276,000 after buying an additional 5,468 shares during the last quarter. Hedge funds and other institutional investors own 64.43% of the company’s stock.
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
- Five stocks we like better than Enfusion
- Why Invest in High-Yield Dividend Stocks?
- Williams-Sonoma is a steal for buy-and-hold investors
- Pros And Cons Of Monthly Dividend Stocks
- A closer look at Warren Buffett’s latest surprise purchase
- Stock Splits, Do They Really Impact Investors?
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.